Hypophosphatemia in a patient with lymphoma in leukemic phase.
A patient with histiocytic lymphoma had abdominal masses, hypophosphatemia, normocalcemia, and a normal serum parathyroid hormone value. After chemotherapy, transient hyperphosphatemia ensued, the abdominal masses resolved, and other manifestations of the disease were suppressed. One week after discontinuation of the chemotherapy, the abdominal masses and other signs indicative of reactivation of the malignant disease reappeared. During the relapse, the serum phosphorus level fell to 0.7 mg/dL, and urinary excretion of phosphorus became negligible. After resumption of chemotherapy, serum concentration and urinary excretion of phosphorus increased. These observation suggest that severe hypophosphatemia may be a complication of hematologic neoplasia. It is proposed that this abnormally may be caused by a shift of excessive amounts of extracellular phosphorus into the rapidly replicating malignant cells.
D000971:Antineoplastic Combined Chemotherapy Protocols; D002118:Calcium / Q000097:blood; D004359:Drug Therapy, Combination; D005110:Extracellular Space / Q000378:metabolism; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000188:drug therapy; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D010758:Phosphorus / Q000097:blood*; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D010281:Parathyroid Hormone; D010710:Phosphates; D010758:Phosphorus; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D002118:Calcium; D011241:Prednisone